BRISTOL MYERS SQUIBB CO
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
BMY$62.140.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2024 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2024 | MDS | myelodysplastic syndromes |
|---|---|---|---|
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of senior unsecured notes issued by BMS in February 2024 | Merck | Merck & Co. |
| 2seventy bio | 2seventy bio, Inc. | Mirati | Mirati Therapeutics, Inc. |
| aGVHD | acute graft-versus-host disease | MPM | malignant pleural mesothelioma |
| ADC | antibody-drug conjugate | MSI-H | microsatellite instability-high |
| ADP | adenosine diphosphate | MTA | Methylthioadenosine |
| ANDA | Abbreviated New Drug Application | MZL | marginal zone lymphoma |
| AOCI | Accumulated other comprehensive loss | NDA | New Drug Application |
| AstraZeneca | AstraZeneca PLC | nHCM | Nonobstructive Hypertrophic Cardiomyopathy |
| BCMA | B-cell maturation antigen-directed | NHL | Non-Hodgkin's Lymphoma |
| BioArctic | BioArctic AB | NKT | natural killer T |
| BioNTech | BioNTech SE | NSCLC | non-small cell lung cancer |
| CAR-T | chimeric antigen receptor T-cell | NTRK | Neurotrophic Tropomyosin Receptor Kinase |
| Celgene | Celgene Corporation | Nimbus | Nimbus Therapeutics |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | NVAF | non-valvular atrial fibrillation |
| CGDP | Coverage Gap Discount Program | OECD | Organization for Economic Co-operation and Development |
| CHMP | Committee for Medicinal Products for Human Use | oHCM | Obstructive Hypertrophic Cardiomyopathy |
| CLL | Chronic Lymphocytic Leukemia | Ono | Ono Pharmaceutical Co., Ltd |
| CML | chronic myeloid leukemia | ORR | overall response rate |
| CRC | colorectal carcinoma | PD-1 | programmed cell death protein 1 |
| CTLA4 | Cytotoxic T-lymphocyte Antigen-4 | PD-L1 | programmed death-ligand 1 |
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act |
| DLBCL | Diffuse Large B-cell Lymphoma | PE | pulmonary embolism |
| dMMR | mismatch repair deficient | Philochem | Philochem AG |
| DVT | deep vein thrombosis | PRMT5 | protein arginine methyltransferase 5 |
| EC | European Commission | PsA | psoriatic arthritis |
| Eisai | Eisai Co., Ltd. | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 |
| EMA | European Medicines Agency | R&D | research and development |
| EPS | earnings per share | RA | rheumatoid arthritis |
| ES-SCLC | extensive stage small cell lung cancer | RayzeBio | RayzeBio, Inc. |
| EU | European Union | RCC | renal cell carcinoma |
| Exchange Act | the Securities Exchange Act of 1934 | RDFV | readily determinable fair values |
| FASB | Financial Accounting Standards Board | REMS | risk evaluation and mitigation strategy |
| FDA | U.S. Food and Drug Administration | Roche | F. Hoffman-La Roche & Co. |
| FL | follicular lymphoma | RPT | radiopharmaceutical therapeutics |
| GAAP | generally accepted accounting principles | RS | ring sideroblast |
| GTN | gross-to-net | Sanofi | Sanofi S.A. |
| HCC | hepatocellular carcinoma | SEC | U.S. Securities and Exchange Commission |
| HCM | hypertrophic cardiomyopathy | SLL | Small Lymphocytic Lymphoma |
| HHS | Health and Human Services | SPC | Supplementary Protection Certificate |
| IPRD | in-process research and development | SystImmune | SystImmune, Inc. |
| IRA | Inflation Reduction Act of 2022 | TCJA | Tax Cuts and Jobs Act of 2017 |
| IRS | Internal Revenue Service | TNBC | triple negative breast cancer |
| JIA | juvenile idiopathic arthritis | UC | ulcerative colitis |
| Karuna | Karuna Therapeutics, Inc. | UK | United Kingdom |
| KRAS | Kirsten rat sarcoma | U.S. | United States |
| LBCL | Large B-cell Lymphoma | VAT | value added tax |
| MCL | mantle cell lymphoma | VEGF-A | Vascular endothelial growth factor A |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.